-Bloomberg
Guggenheim Maintains Buy on Cogent Biosciences, Raises Price Target to $24
Guggenheim analyst Charles Zhu maintains Cogent Biosciences (NASDAQ:COGT) with a Buy and raises the price target from $22 to $24.
Related Posts
RBC Capital Sees Sharp Upside In This Direct Beneficiary Of Russia’s Invasion Of Ukraine
AeroVironment, Inc. (NASDAQ:AVAV) has been upgraded to Outperform from Sector Perform, and the price target was raised to $100 (an…
Saia Earlier Reported Q2 EPS $2.34 Beats $2.00 Estimate, Sales $571.33M Beat $546.21M Estimate
Saia (NASDAQ:SAIA) reported quarterly earnings of $2.34 per share which beat the analyst consensus estimate of $2.00 by 17 percent. This is a 118.69 percent increase over earnings of $1.07 per share from the same period